LONDON--(BUSINESS WIRE)--The viral vectors market is poised to grow by USD 385.78 million during 2020-2024, progressing at a CAGR of almost 15% during the forecast period.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Download Free Sample Report on COVID-19 Recovery Analysis
The report on the viral vectors market provides a holistic update, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the rising prevalence of chronic diseases.
The viral vectors market analysis includes application segment and geography landscape. This study identifies the emergence of novel technologies to manufacture viral vectors as one of the prime reasons driving the viral vectors market growth during the next few years.
This report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters.
The viral vectors market covers the following areas:
Viral Vectors Market Sizing
Viral Vectors Market Forecast
Viral Vectors Market Analysis
Companies Mentioned
- Asklepios BioPharmaceutical Inc.
- Batavia Biosciences BV
- Cobra Biologics Ltd.
- Creative Biogene
- FinVector Oy
- Lonza Group Ltd.
- Merck KGaA
- Novasep Holding SAS
- Oxford Biomedica Plc
-
Thermo Fisher Scientific Inc.
Key Topics Covered:
Executive Summary
Market Landscape
- Market ecosystem
- Market characteristics
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 – 2024
Five Forces Analysis
- Five forces summary
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Application
- Market segments
- Comparison by Application
- Gene therapy - Market size and forecast 2019-2024
- Vaccines - Market size and forecast 2019-2024
- Market opportunity by Application
Customer Landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- Asia - Market size and forecast 2019-2024
- ROW - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Vendors covered
- Market positioning of vendors
- Asklepios BioPharmaceutical Inc.
- Batavia Biosciences BV
- Cobra Biologics Ltd.
- Creative Biogene
- FinVector
- Lonza Group Ltd.
- Merck KGaA
- Novasep Holding SAS
- Oxford Biomedica Plc
- Thermo Fisher Scientific Inc.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
-
List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
